| Document |
Document Title |
|
WO2006060122A9 |
The present invention provides compounds possessing inhibitory activity against ß adrenergic receptors and phosphodiesterase (PDE), including type 3 phosphodiesterase (PDE-3). The present invention further provides pharmaceutical compos...
|
|
WO/2006/086447A2 |
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (Ia): where x, y, W, V, R2, R3, R4, R5,...
|
|
WO/2006/083271A2 |
The invention provides certain acylthiourea derivatives and pharmaceutically acceptable salts thereof. These compounds possess potent antiviral activity. The invention particularly provides compounds that are potent and/or selective inhi...
|
|
WO/2006/080323A1 |
A compound that can be used as a pharmaceutical active ingredient effective in prevention and/or treatment of osteoporosis, a bone disease such as fracture, and further, glaucoma or ulcerative colitis, and is represented by the general f...
|
|
WO/2006/077851A1 |
Disclosed is a compound having an excellent platelet agglutination inhibitory effect. Specifically disclosed is a quinolone derivative characterized by having an amide group at the 3-position which is substituted with a substituent havin...
|
|
WO/2006/076706A1 |
The present invention provides novel cinnamide compounds of formula (I) useful as inhibitors of raf -protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and use thereof in th...
|
|
WO/2006/069808A2 |
The present invention relates to nitro-substituted phenyl-piperazine compounds of general formula I, a process for their preparation, medicaments comprising said nitro-substituted phenyl-piperazine compounds as well as the use of said ni...
|
|
WO/2006/070878A1 |
It is intended to provide a compound which has an anticoagulant effect based on the inhibition of the activated blood coagulation factor VII and, therefore, is useful as a blood coagulation inhibitor or a preventive/remedy for diseases c...
|
|
WO/2006/060127A2 |
This invention provides compounds that possess inhibitory activity against β-adrenergic receptors and phosphodiesterases, including phosphodiesterase 3 (PDE3). This invention further provides pharmaceutical compositions comprising such ...
|
|
WO/2006/041119A1 |
Compounds represented by the general formula (1) or salts thereof, or hydrates of both, which are safe and have moderate physicochemical stability and which are useful as preventive or therapeutic agents for diseases caused by thrombus f...
|
|
WO/2006/036981A2 |
The present invention provides compounds having formula (I) or (II): Formula (I), formula (II) and pharmaceutically acceptable derivatives thereof, wherein m, p, R1, R2, R3 and R4 are as described generally and in classes and subclasses ...
|
|
WO/2006/034341A2 |
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, G, J, K, L, M, Q, W, V,...
|
|
WO/2006/029799A1 |
The invention relates to novel iodine-phenyl-substituted cyclic cetoenols of formula (I) wherein CKE, J, X and Y have the above-mentioned meanings, several methods and intermediate products for the production thereof and the use thereof ...
|
|
WO/2006/027236A1 |
The invention relates to alkylidene tetrahydronaphthalene derivatives of general formula (I), to methods for their production and to their use as anti-inflammatory agents.
|
|
WO/2006/028957A1 |
The present disclosure relates generally to the field of phosphodiesterase 10 (PDE10) enzyme inhibition by cinnoline compounds of Formulas: (I) and (II); wherein R'-R3 and R15-R18 are as defined herein. Still further, the present inventi...
|
|
WO/2006/024034A1 |
Heterocyclic compounds derived from benzotriazine, triazines, triazoles and oxadiazoles are disclosed. The methods of synthesis and of use of such heterocyclic compounds are also provided.
|
|
WO/2006/015828A1 |
Compounds which potentiate glutamate receptor and uses thereof in medicine Compounds of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof, are disclosed: wherein R1 is C1-6alkyl, haloC1-6 alkyl, C2-6alkenyl, a...
|
|
WO/2006/015859A1 |
The invention relates to trifluoromethyl substituted benzamide compounds of the formula (I), pharmaceuticals comprising these compounds, their use as or for the manufacture of pharmaceuticals, particularly as inhibitors of protein kina...
|
|
WO/2006/016194A1 |
Compounds of Formula (I) wherein R1 is a cycloalkylsulphonyl group, or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.
|
|
WO2005113511A9 |
The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods fo...
|
|
WO/2006/009134A1 |
A novel fungicide that exhibits a wide disease control spectrum against pathogenic fungi acting on various crops and helps resolve worsening resistant strain problems. There are provided diamine derivatives of the formula (1), a process ...
|
|
WO/2006/009054A1 |
[PROBLEMS] To provide a compound that is useful as a nitrogen monoxide production accelerator and/or endothelial nitrogen monoxide synthetic enzyme activator. [MEANS FOR SOLVING PROBLEMS] The phenethylnicotinamide compound as an active i...
|
|
WO/2006/003495A1 |
The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists...
|
|
WO/2006/001175A1 |
Disclosed is a pyridazine compound represented by the formula (1) below which has an excellent effect on controlling plant diseases.
|
|
WO/2006/000333A1 |
The present invention relates to compounds of the formula (I), wherein the substituents have the meaning given in the description, the use of these compounds as plant treatment agents and pesticides, and different methods for the product...
|
|
WO/2005/123693A1 |
The invention relates to new therapeutically useful pyridazin-3(2H)-one derivatives, to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent and selective inhibitors of phosphodie...
|
|
WO/2005/122682A2 |
The present invention provides simple and cost effective processes to prepare esters of piperazic acid, which can be useful as intermediates in synthesizing cilazapril. Key feature is treating 2, 5-dibromovaleric acid with tert-butanol i...
|
|
WO/2005/123692A1 |
The invention relates to new therapeutically useful pyridazin-3(2H)-one derivatives of Formula (I) and to pharmaceutical compositions containing them. These compounds are potent and selective inhibitors of phosphodiesterase 4 (PDE4) and ...
|
|
WO/2005/121105A1 |
A 3-phenyltetrahydrocinnolin-5-ol derivative represented by the following general formula (1) (wherein Z represents 2-carboxyethyl, 3-dimethylaminopropyl, etc.; X represents trifluoromethyl, etc.; X' represents hydrogen, etc.; and Y and ...
|
|
WO/2005/121104A1 |
A pyridazine compound represented by the formula (1). (1) It is highly effective in controlling plant diseases.
|
|
WO/2005/117883A1 |
The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
|
|
WO/2005/117876A1 |
The present invention provides analogs and derivatives of thalidomide which inhibit cancer and angiogenesis. The present invention further provides compounds which disrupt microtubule polymerization. The present further provides methods ...
|
|
WO/2005/115992A1 |
This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variant...
|
|
WO/2005/115972A1 |
Compounds of formula I or pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, m and n are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are ...
|
|
WO/2005/115983A1 |
Aryl sulfonamide and sulfonyl compounds of formula (I) as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.
|
|
WO/2005/112945A2 |
The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among man...
|
|
WO/2005/108373A1 |
The invention relates to the novel beta agonists of general formula (I); wherein the groups R1 to R7 are defined as in the claims and the description, and to the tautomers, enantiomers, diastereomers, mixtures, prodrugs and salts thereof...
|
|
WO/2005/103033A1 |
The invention relates to 1-amino-phthalazine derivatives of general formula (I), wherein A, B = possibly substituted C1-4-alkylene; L = a simple bond or C1-2-alkylene, possibly substituted -CH=CH-, or -C=C- or cycloprop-1,2--diyl; R1 = p...
|
|
WO/2005/100323A1 |
The present invention provides a process for the preparation 6-[3-(hetero)aryloxy-2-fluoro-benzyl] -2H-pyridazin-3-one compounds of formula VIII wherein R2 is an optionally substituted aryl or an optionally substituted heteroaryl, X is...
|
|
WO/2005/099688A2 |
There is provided a CRF receptor antagonist comprising a compound of the formula (I): A-W-Ar wherein, A is a group represented by the formula (A1) or (A2) (wherein, ring Aa is a 5-or 6-membered ring which may be further substituted; ring...
|
|
WO2005030794B1 |
The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R7, X1, X2, R, Q, and n are as defined herein.
|
|
WO/2005/092899A1 |
The invention relates to a series of compounds useful for inhibiting histone deacetylase (HDAC) enzymatic activity. The invention also provides a method for inhibiting histone descetylase in a cell using said compounds as well as a metho...
|
|
WO/2005/090292A1 |
The invention relates to a compound having general formula (I), wherein: A is selected from among one or more X, Y and/or Z groups; X represents an optionally-substituted methylene group; Y represents a C2-alkenylene, optionally substitu...
|
|
WO/2005/090317A1 |
The present invention relates to a compounds according to formula (I), methods for treating diseases mediated by human immunodeficieny virus by administration of a compound according to formula (I) and pharmaceutical compositions for tre...
|
|
WO/2005/085200A1 |
Disclosed is a pyridone derivative represented by the following formula (I). [In the formula, R1 and R2 may be the same or different and respectively represent H or the like, or alternatively R1 and R2 may form an aliphatic nitrogen-cont...
|
|
WO/2005/082871A2 |
The invention relates to guanidine compounds of general formula (I), corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and pharmaceutically acceptable salts thereof. The invention further relates to the use of ...
|
|
WO/2005/080361A1 |
This invention is directed to a compound of the formula (I) as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula (I), a method of treatment of a disorder or condi...
|
|
WO/2005/080317A2 |
The present invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: A and B independently represent CH2 or O, with the proviso that A and B are not simultaneously O; Cy repres...
|
|
WO/2005/077914A1 |
The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating &agr 4 integrin mediated disorders. More particularly, the pyridazinon...
|
|
WO/2005/076861A2 |
The present invention describes novel methods of identifying compounds which inhibit HIV particle formation and Rev-dependent HIV production. The present invention also provides methods and compounds for inhibiting HIV particle formation...
|
